Lifelong Kidney Transplant Medicines May Be Covered Under Free Treatment Scheme: Delhi HC
New Delhi: The Delhi High Court has observed that medicines required throughout life following a kidney transplant may be included under the free medical treatment provisions of the applicable government scheme. In an interim order, the court directed the Centre to continue reimbursing the medical expenses incurred by petitioner Surendra Kumar for medicines prescribed after his kidney transplant.
The matter relates to Kumar’s request for reimbursement of expenses towards essential post-transplant medicines under the National Arogya Nidhi. The petitioners argued that medical treatment does not conclude with the completion of transplant surgery and that medicines necessary to maintain the transplanted organ should also be covered under the scheme.
While considering the matter, the court observed that organ transplantation represents only one component of the overall treatment process. It noted that there was no dispute regarding the requirement for kidney transplant recipients to take medicines throughout their lives following the procedure. Accordingly, the court expressed a prima facie view that the expenses incurred on such medicines could also fall within the scope of the free-treatment scheme.
The court’s observations highlight the importance of continued medical care following organ transplantation. Kidney transplant recipients generally require lifelong medication to maintain the functioning of the transplanted organ and prevent complications, including organ rejection. The petition raised the issue of whether government-supported treatment provisions should extend beyond the surgical procedure to include essential medicines required during the post-transplant period.
Providing interim relief to Kumar, the court directed the Centre to continue reimbursing his medicine expenses. However, the direction is specific to the petitioner’s case and does not constitute a final nationwide ruling modifying the reimbursement provisions or eligibility criteria under the National Arogya Nidhi.
The matter also raises broader concerns regarding the interpretation of government-funded healthcare schemes and the financial burden associated with long-term treatment. While a procedure-focused approach may limit financial assistance to the transplant surgery, a broader interpretation could recognise essential post-operative medicines as an integral part of the treatment required to sustain the success of the procedure. The court’s prima facie observations address this distinction in the present case.
Additionally, the proceedings highlight the challenges faced by transplant recipients in securing reimbursement for medicines prescribed after discharge from hospitals. Although patients undergo transplantation as part of their medical treatment, their continued recovery and management depend on uninterrupted access to prescribed medicines and an effective reimbursement mechanism. The court’s interim direction requires the Centre to maintain reimbursement for Kumar while the legal issues remain under consideration.
According to a recent media report in Urban Acres, the matter is scheduled for further hearing on February 4, 2027, when the court will continue examining the petitioners’ request for coverage of lifelong post-kidney transplant medicines under the National Arogya Nidhi. Further proceedings will determine whether any broader directions concerning post-transplant treatment and reimbursement are issued.
